Phase II study on the combination of irinotecan plus cisplatin as a second-line therapy in patients with advanced or recurrent gastric cancer

A pilot phase II study was conducted to evaluate the efficacy and safety of the combined administration of irinotecan (CPT-11) plus cisplatin (CDDP) as a second-line therapy for advanced or recurrent gastric cancer. Between November, 2006 and May, 2009, 18 patients were enrolled in this study. The p...

Descripción completa

Detalles Bibliográficos
Autores principales: RINO, YASUSHI, YUKAWA, NORIO, SATO, TSUTOMU, OSHIMA, TAKASHI, TANABE, HIROYASU, YAMAMOTO, YUJI, MATSUKAWA, HIROSHI, SHIRAISHI, RYUJI, IMADA, TOSHIO, MASUDA, MUNETAKA
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2013
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3915670/
https://www.ncbi.nlm.nih.gov/pubmed/24649240
http://dx.doi.org/10.3892/mco.2013.115

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3915670/
https://www.ncbi.nlm.nih.gov/pubmed/24649240
http://dx.doi.org/10.3892/mco.2013.115

Ejemplares similares